Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Net Income Loss of -$101.1 thousand for the year ending 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -139.1% in Net Income Loss from 2024 to 2025.
- This data is from ACRO BIOMEDICAL CO., LTD.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$29.00 | Q2 2015: -$18.00 | Q4 2015: -$13.8 thousand | Q1 2016: -$6.4 thousand | Q2 2016: -$17.1 thousand | Q4 2016: -$7.4 thousand | Q1 2017: -$22.4 thousand | Q2 2017: -$11.9 thousand | Q4 2017: $80.2 thousand | Q1 2018: $69.5 thousand | Q2 2018: $116.3 thousand | Q4 2018: -$75.0 thousand | Q1 2019: -$169.8 thousand | Q2 2019: -$50.8 thousand | Q3 2019: -$75.2 thousand | Q4 2019: -$75.9 thousand | Q1 2020: $81.1 thousand | Q2 2020: -$63.7 thousand | Q3 2020: -$73.1 thousand | Q1 2021: -$59.5 thousand | Q2 2021: -$794.7 thousand | Q3 2021: -$2.99 million | Q1 2022: -$3.93 million | Q2 2022: -$4.00 million | Q3 2022: -$4.01 million | Q1 2023: -$4.00 million | Q2 2023: -$3.20 million | Q3 2023: -$1.59 million | Q1 2024: -$11.3 thousand | Q2 2024: -$10.1 thousand | Q3 2024: -$10.2 thousand | Q1 2025: -$10.3 thousand | Q2 2025: -$15.6 thousand | Q3 2025: -$117.8 thousand.
- Over the full 12 years of available data (2015 to 2025), ACRO BIOMEDICAL CO., LTD.'s Net Income Loss has declined by 113.0%.
- Historical annual values: Fiscal year 2025: -$101.1 thousand | Fiscal year 2024: -$42.3 thousand | Fiscal year 2023: -$8.81 million | Fiscal year 2022: -$15.87 million | Fiscal year 2021: -$7.70 million | Fiscal year 2020: -$117.5 thousand | Fiscal year 2019: -$371.6 thousand | Fiscal year 2019: -$370.7 thousand | Fiscal year 2018: $419.7 thousand | Fiscal year 2017: -$2.2 thousand | Fiscal year 2016: -$43.4 thousand | Fiscal year 2015: -$47.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: